FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:68-69 July 6, 2000 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Maron, B. J. PubMed Citation

To the Editor: In the retrospective study by Maron et al. (Feb. 10 issue)¹ of patients with hypertrophic cardiomyopathy who received implantable cardioverter–defibrillators, the rate of appropriate discharge was quite high when the device was implanted in patients with hypertrophic cardiomyopathy after resuscitation from cardiac arrest. Clearly, some form of therapy is required for such patients.

However, the conclusion by Maron et al. that the use of an implantable cardioverter–defibrillator is warranted for the primary prevention of sudden death in high-risk patients with hypertrophic cardiomyopathy is not sufficiently supported by the available evidence. The authors report that there was a . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.